Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

Phase 1 Completed 33 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, use different ways to stop tumor cells from dividing so they stop growing or die. Pemetrexed disodium may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of pemetrexed disodium in treating young patients with recurrent solid tumors.

Timeline

Start: 2003-10
Primary completion: 2006-03
Completion: 2008-06

Publications

Results Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC; Children's Oncology Group. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol. 2007 Apr 20;25(12):1505-11. doi: 10.1200/JCO.2006.09.1694.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pemetrexed	Small molecule	400 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	520 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	670 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	870 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	1130 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	1470 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	1910 mg/m2	Intravenous
Subject	Pemetrexed	Small molecule	2480 mg/m2	Intravenous

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

Summary

Timeline

Publications

Drugs

Indications